Detalhe da pesquisa
1.
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.
Gynecol Oncol
; 161(2): 496-501, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33637348
2.
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.
Gynecol Oncol
; 157(3): 578-584, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32265057
3.
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
J Clin Oncol
; 42(2): 170-179, 2024 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37906726
4.
Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.
Clin Cancer Res
; 29(20): 4186-4195, 2023 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37540556
5.
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).
Neuro Oncol
; 22(5): 705-717, 2020 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31844890
6.
Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study.
Neuro Oncol
; 22(5): 694-704, 2020 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31844886
7.
Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study.
Arthritis Rheumatol
; 66(11): 3241-3, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25049046